Braveheart Bio director buys 4,166 shares at $18
Braveheart Bio, Inc. director David I. Malek reported two equity-related events.
Rhea-AI Filing Summary
Braveheart Bio, Inc. director David I. Malek reported two equity-related events. On August 7, 2026 he purchased 4,166 shares of Common Stock at $18.00 per share, bringing his directly held Common Stock to 533,845 shares. On August 5, 2026 he also received a grant of stock options for 30,000 shares of Common Stock with an exercise price of $18.00 per share, expiring on August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service. In addition, 239,726 shares are reported as held indirectly by Malek Trust YM and 239,726 shares by Malek Trust NM, with beneficial ownership disclaimed except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,166 shares
Net Buy
4 txns
Insider
Malek David I
Role
Director
Bought
4,166 shs ($75K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 4,166 | $18.00 | $75K |
| Grant/Award | Stock Option (Right to Buy) F2 | 30,000 | $0.00 | $0.00 |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,000 contracts (Direct);
Common Stock — 533,845 shares (Direct);
Common Stock — 239,726 shares (Indirect, By Malek Trust YM);
Common Stock — 239,726 shares (Indirect, By Malek Trust NM)
Footnotes (2)
- F1. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- F2. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Key Figures
Open-market purchase: 4,166 shares of Common Stock at $18.00 per share
Direct holdings after purchase: 533,845 shares of Common Stock
Stock option grant size: 30,000 options for Common Stock at $18.00 per share
+3 more
6 metrics
Open-market purchase
4,166 shares of Common Stock at $18.00 per share
Purchased by director David I. Malek on August 7, 2026
Direct holdings after purchase
533,845 shares of Common Stock
Directly held by David I. Malek following the August 7, 2026 transaction
Stock option grant size
30,000 options for Common Stock at $18.00 per share
Granted on August 5, 2026, expiring August 4, 2036
Option expiration date
August 4, 2036
Expiration of 30,000-share stock option grant to David I. Malek
Malek Trust YM indirect holding
239,726 shares of Common Stock
Held indirectly "By Malek Trust YM" with beneficial ownership disclaimed except pecuniary interest
Malek Trust NM indirect holding
239,726 shares of Common Stock
Held indirectly "By Malek Trust NM" with beneficial ownership disclaimed except pecuniary interest
Key Terms
stock option, exercise price, beneficial ownership, pecuniary interest, +1 more
5 terms
stock option financial
"The shares underlying the stock option will vest in full upon the earlier"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "18.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such securities for purposes"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BRVE director David I. Malek report?
David I. Malek purchased 4,166 shares of Braveheart Bio Common Stock at $18.00 per share on August 7, 2026, increasing his directly held Common Stock position to 533,845 shares after the transaction.
Did BRVE grant stock options to David I. Malek in this Form 4?
Yes. On August 5, 2026, David I. Malek received a stock option grant for 30,000 shares at an exercise price of $18.00 per share, expiring August 4, 2036, with vesting on the earlier of August 5, 2027 or the next annual meeting.
What indirect holdings in BRVE are reported for trusts associated with David I. Malek?
The filing reports 239,726 shares of Braveheart Bio Common Stock held indirectly by Malek Trust YM and another 239,726 shares held by Malek Trust NM. Malek disclaims beneficial ownership except to the extent of any pecuniary interest.
When do David I. Malek’s newly granted BRVE stock options vest?
The 30,000-share stock option grant will vest in full on the earlier of August 5, 2027 or the date of Braveheart Bio’s next annual stockholder meeting, subject to Malek’s continued service to the company through the vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
